Synthesis and structure of high potency RNA therapeutics
This invention provides expressible polynucleotides, which can express a target protein or polypeptide. Synthetic mRNA constructs for producing a protein or polypeptide can contain one or more 5′ UTRs, where a 5′ UTR may be expressed by a gene of a plant. In some embodiments, a 5′ UTR may be expressed by a gene of a member of Arabidopsis genus. The synthetic mRNA constructs can be used as pharmaceutical agents for expressing a target protein or polypeptide in vivo.
1 . A synthetic mammalian mRNA expression construct for producing a protein or polypeptide, the synthetic mammalian mRNA expression construct comprising a 5′ UTR, wherein the 5′ UTR consists of the sequence of SEQ ID NO:31.
2 . The synthetic mammalian mRNA expression construct of claim 1 , wherein the synthetic mammalian mRNA expression construct comprises a 3′ UTR consisting of a sequence selected from SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO: 81, SEQ ID NO: 83, SEQ ID NO:84, SEQ ID NO: 87, and SEQ ID NO:91.
3 . The synthetic mammalian mRNA expression construct of claim 1 , wherein the synthetic mammalian mRNA expression construct comprises a 3′ UTR selected from human beta globin (hBG), mouse albumin (mALB), human alpha globin (hAG), human growth hormone 1 (ARC3-2), human apolipoprotein E (hApolipoprotein E), Alanine amino transferase, human growth factor (hGF), human complement 3 (hC3), and human antithrombin (hAntithrombin).
4 . The synthetic mammalian mRNA expression construct of claim 1 , wherein the synthetic mammalian mRNA expression construct comprises a 5′ cap, a coding sequence for encoding the protein or polypeptide, a 3′ UTR, and a poly(A) or poly(C) tail.
5 . The synthetic mammalian mRNA expression construct of claim 1 , wherein the synthetic mammalian mRNA expression construct further comprises a Kozak sequence and a coding sequence encoding a protein deficient in a rare disease,
wherein the rare disease is Aminoacylase 1 deficiency, Apo A-I deficiency, Carbamoyl phosphate synthetase 1 deficiency, Ornithine transcarbamylase deficiency, Plasminogen activator inhibitor type 1 deficiency, Flaujeac factor deficiency, High-molecular-weight kininogen deficiency congenital, PEPCK 1 deficiency, Pyruvate kinase deficiency liver type, Alpha 1-antitrypsin deficiency, Anti-plasmin deficiency congenital, Apolipoprotein C 2I deficiency, Butyrylcholinesterase deficiency, Complement component 2 deficiency, Complement component 8 deficiency type 2, Congenital antithrombin deficiency type 1, Congenital antithrombin deficiency type 2, Congenital antithrombin deficiency type 3, Cortisone reductase deficiency 1, Factor VII deficiency, Factor X deficiency, Factor XI deficiency, Factor XII deficiency, Factor XIII deficiency, Fibrinogen deficiency congenital, Fructose-1 6-bisphosphatase deficiency, Gamma aminobutyric acid transaminase deficiency, Gamma-cystathionase deficiency, Glut2 deficiency, GTP cyclohydrolase I deficiency, Isolated growth hormone deficiency type 1B, Molybdenum cofactor deficiency, Prekallikrein deficiency congenital, Proconvertin deficiency congenital, Protein S deficiency, Pseudocholinesterase deficiency, Stuart factor deficiency congenital, Tetrahydrobiopterin deficiency, Type 1 plasminogen deficiency, Urocanase deficiency, Chondrodysplasia punctata with steroid sulfatase deficiency, Homocystinuria due to CBS deficiency, Guanidinoacetate methyltransferase deficiency, Pulmonary surfactant protein B deficiency, Acid Sphingomyelinase Deficiency, Adenylosuccinate Lyase Deficiency, Aggressive Angiomyxoma, Albrights Hereditary Osteodystrophy, Carney Stratakis Syndrome, Carney Triad Syndrome, CDKL5 Mutation, CLOVES Syndrome, Cockayne Syndrome, Congenital Disorder of Glycosylation type 1R, Cowden Syndrome, DEND Syndrome, Dercum's Disease, Febrile Infection-Related Epilepsy Syndrome, Fibular Aplasia Tibial Campomelia Oligosyndactyly Syndrome, Food Protein-Induced Enterocolitis Syndrome, Foreign Body Giant Cell Reactive Tissue Disease, Galloway-Mowat, Gitelman syndrome, Glycerol Kinase Deficiency, Glycogen Storage Disease type 9, gm1 gangliosidosis, Hereditary spherocytosis, Hidradenitis Suppurativa Stage III, Horizonatal Gaze Palsy with Progressive Scoliosis, IMAGe syndrome, Isodicentric chromosome 15, isolated hemihyperplasia, Juvenile Xanthogranuloma, Kasabach-Merritt Syndrome, Kniest Dysplasia, Koolen de-Vries Syndrome, Lennox-Gastaut syndrome, Lymphangiomatosis, Lymphangiomiomytosis, MASA Syndrome, Mast Cell Activation disorder, Mecp2 Duplication Syndrome, Mucha Habermann, Neonatal Hemochromatosis, N-glycanase deficiency, Opsoclonus Myoclonus Syndrome, Persistent genital arousal disorder, Pompe Disease, Progressive Familial Intrahepatic Cholestasis, Pseudohypoparathyroidism type 1a, PTEN Hamartoma Tumor Syndrome, Schnitzler syndrome, Scleroderma, Semi Lobar Holoprosencephany, Sjogren's Syndrome, Specific Antibody Deficiency Disease, SYNGAP 1 deficiency, Trigeminal Trophic Syndrome, Undifferentiated Connective Tissue Disease, or X-linked hypophosphatemia.
6 . The synthetic mammalian mRNA expression construct of claim 1 , wherein the synthetic mammalian mRNA expression construct comprises a coding sequence for encoding the protein or polypeptide, wherein the coding sequence comprises a sequence selected from SEQ ID NO:130, SEQ ID NO:124, SEQ ID NO:122, or a codon-optimized variant thereof.
7 . The synthetic mammalian mRNA expression construct of claim 1 , wherein the protein or polypeptide is a human rare disease protein.
8 . The synthetic mammalian mRNA expression construct of claim 1 , wherein the protein or polypeptide is human ornithine transcarbamylase (hOTC).
9 . The synthetic mammalian mRNA expression construct of claim 1 , wherein the synthetic mammalian mRNA expression construct comprises a 5′ cap, a Kozak sequence of SEQ ID NO:121, a coding sequence encoding human ornithine transcarbamylase (hOTC), a human alpha globin (hAG) 3′ UTR consisting of the sequence of SEQ ID NO:81, and a poly(A) tail.
10 . The synthetic mammalian mRNA expression construct of claim 1 , wherein the protein or polypeptide is selected from Aminoacylase 1, Apo A-I, Carbamoyl phosphate synthetase 1, Ornithine transcarbamylase, Plasminogen activator inhibitor type 1, Flaujeac factor (High-molecular-weight kininogen), PEPCK 1, Pyruvate kinase liver type, Alpha 1-antitrypsin, Anti-plasmin, Apolipoprotein C 2I, Butyrylcholinesterase, Complement component 2, Complement component 8 type 2, Antithrombin, Antithrombin type 2, Antithrombin type 3, Cortisone reductase, Factor VII, Factor IX, Factor X, Factor XI, Factor XII, Factor XIII, Fibrinogen, Fructose-1 6-bisphosphatase, Gamma aminobutyric acid transaminase, Gamma-cystathionase, Glut2, GTP cyclohydrolase I, Isolated growth hormone type 1B, Molybdenum cofactor, Prekallikrein, Proconvertin, Protein S, Pseudocholinesterase, Stuart factor, Tetrahydrobiopterin, Plasminogen, Urocanase, steroid sulfatase, cystathionine beta-synthase (CBS), Guanidinoacetate methyltransferase, Pulmonary surfactant protein B, Acid Sphingomyelinase, Adenylosuccinate Lyase, CDKL5, Glycerol Kinase, Mecp2, N-glycanase, PTEN, and SYNGAP 1.
11 . The synthetic mammalian mRNA expression construct of claim 1 , wherein
(a) a coding sequence for encoding the protein or polypeptide has alternative codons as compared to a native mRNA encoding the protein or polypeptide;
(b) a coding sequence for encoding the protein or polypeptide has a high codon adaptation index;
(c) one or more codons of a codon-optimized coding sequence of the synthetic mammalian mRNA expression construct that encodes the protein or polypeptide have been replaced such that the occurrence of uridine monomers in the codon-optimized coding sequence is reduced as compared to the coding sequence of a native mRNA encoding the protein or polypeptide; or
(d) (a), (b), and (c).
12 . The synthetic mammalian mRNA expression construct of claim 1 , wherein a coding sequence of the synthetic mammalian mRNA expression construct, the 5′ UTR, or both a coding sequence of the synthetic mammalian mRNA expression construct and the 5′ UTR comprise one or more chemically-modified nucleotides selected from the group of
5-hydroxyuridine, 5-methyluridine, 5,6-dihydro-5-methyluridine, 2′-O-methyluridine, 2′-O-methyl-5-methyluridine, 2′-fluoro-2′-deoxyuridine, 2′-amino-2′-deoxyuridine, 2′-azido-2′-deoxyuridine, 4-thiouridine, 5-hydroxymethyluridine, 5-carboxyuridine, 5-carboxymethylesteruridine, 5-formyluridine, 5-methoxyuridine, 5-propynyluridine, 5-bromouridine, 5-iodouridine, 5-fluorouridine;
pseudouridine, 2′-O-methyl-pseudouridine, N1-hydroxypseudouridine, N1 -methylpseudouridine, 2′-O-methyl-N1-methylpseudouridine, N1-ethylpseudouridine, N1-hydroxymethylpseudouridine, and Arauridine;
5-hydroxycytidine, 5-methylcytidine, 5-hydroxymethylcytidine, 5-carboxycytidine, 5-formylcytidine, 5-methoxycytidine, 5-propynylcytidine, 2-thiocytidine;
N 6 -methyladenosine, 2-aminoadenosine, 3-methyladenosine, 7-deazaadenosine, 8-oxoadenosine, inosine;
thienoguanosine, 7-deazaguanosine, 8-oxoguanosine, and 6-O-methylguanine.
13 . A DNA template for making the synthetic mammalian mRNA expression construct of claim 1 by in vitro transcription.
14 . A composition comprising the synthetic mammalian mRNA expression construct of claim 1 and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises a transfection reagent, a nanoparticle, or a liposome.
15 . The composition of claim 14 , wherein the nanoparticle is a lipid nanoparticle and comprises a thiocarbamate or carbamate-containing lipid molecule.
16 . The composition of claim 15 , wherein the thiocarbamate or carbamate-containing lipid molecule has Formula I:
wherein
R 1 and R 2 both consist of a branched or linear alkyl consisting of 1 to 14 carbons, or an alkenyl or alkynyl consisting of 2 to 14 carbons;
L 1 and L 2 both consist of a linear alkylene or alkenylene consisting of 5 to 18 carbons, or forming a heterocycle with N;
X is S;
L 3 consists of a bond or a linear alkylene consisting of 1 to 6 carbons, or forming a heterocycle with N;
R 3 consists of a linear or branched alkylene consisting of 1 to 6 carbons; and
R 4 and R 5 are the same or different, each consisting of a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons;
or a pharmaceutically acceptable salt thereof.
17 . The composition of claim 15 , wherein the thiocarbamate or carbamate-containing lipid molecule is selected from ATX-001, ATX-002, ATX-003, ATX-004, ATX-005, ATX-006, ATX-007, ATX-008, ATX-009, ATX-010, ATX-011, ATX-012, ATX-013, ATX-014, ATX-015, ATX-016, ATX-017, ATX-018, ATX-019, ATX-020, ATX-021, ATX-022, ATX-023, ATX-024, ATX-025, ATX-026, ATX-027, ATX-028, ATX-031, ATX-032, ATX-0081, ATX-0095, ATX-0102, and ATX-0126.
18 . An isolated cell or vector comprising the synthetic mammalian mRNA expression construct of claim 1 .